Scientists say immune cell ageing may hold the key to preventing osteoporosis and other chronic bone diseases

As people grow older, weakening bones are often considered an unavoidable part of ageing. However, new research suggests that the decline may be driven not only by ageing bones themselves but also by an ageing immune system.

A recent scientific review has highlighted the growing evidence that immune cell senescence, the gradual deterioration of immune cell function with age—plays a critical role in disrupting the body’s natural process of bone renewal. The findings provide new insights into how age-related changes in the immune system contribute to osteoporosis and other chronic bone disorders while pointing to potential new treatment strategies.

Bone is a living tissue that constantly undergoes remodelling. Specialised cells known as osteoclasts remove old or damaged bone, while osteoblasts build new bone to replace it. During early and middle adulthood, these two processes remain in balance, preserving bone strength and density.

With advancing age, however, this balance begins to shift. Bone breakdown gradually outpaces bone formation, resulting in lower bone mineral density, weakened skeletal structure, and an increased risk of fractures.

Researchers say the ageing immune system is an important factor behind this imbalance. As immune cells age, they undergo widespread functional changes, including reduced ability to multiply, impaired movement to sites of injury, diminished capacity to remove damaged cells, and altered production of inflammatory signalling molecules.

These age-related changes create a persistent state of chronic, low-grade inflammation, commonly known as “inflammaging.” This inflammatory environment disrupts communication between immune cells and bone cells, encouraging excessive bone resorption while suppressing the formation of new bone.

The review also examines how immune cell aging contributes to several chronic skeletal disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, and diabetes-related bone disease. While immune senescence appears to play a direct role in osteoporosis and rheumatoid arthritis, its contribution to osteoarthritis and diabetes-related bone disease is more indirect, primarily by amplifying inflammation and worsening the local tissue environment.

Scientists are now exploring therapies aimed at slowing or reversing immune aging. Experimental approaches include regulating macrophage activity, enhancing the immune system’s ability to eliminate senescent cells, restoring healthy adaptive immune responses, and improving the bone microenvironment using mesenchymal stem cell therapies.

Although these strategies remain largely in preclinical or early translational research, investigators believe they could eventually lead to more effective treatments that target the underlying biological causes of bone degeneration rather than simply managing its symptoms.

The researchers also emphasize the need for advanced technologies such as single-cell sequencing, spatial transcriptomics, and multi-omics analysis to better understand how aging immune cells interact with bone tissue. Such approaches could help identify new biomarkers for early diagnosis and pave the way for precision therapies tailored to individual patients.

The findings reinforce the emerging field of osteoimmunology, which examines the close relationship between the immune and skeletal systems. By revealing how immune aging influences bone health, scientists hope to develop interventions that preserve skeletal strength, reduce fractures, and improve quality of life for the world’s rapidly growing aging population.